Skip to main content

2 Result(s)

within Medicine & Public Health Remove this filter Intensive / Critical Care Medicine Remove this filter Internal Medicine Remove this filter K. Jacobs Remove this filter

and

  1. Article

    Open Access

    Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

    Mutations in the interleukin-7 receptor (IL7R) or the Janus kinase 3 (JAK3) kinase occur frequently in T-cell acute lymphoblastic leukemia (T-ALL) and both are able to drive cellular transformation and the dev...

    S Degryse, C E de Bock, S Demeyer, I Govaerts, S Bornschein, D Verbeke… in Leukemia (2018)

    Download PDF (1915 KB) View Article

  2. Article

    Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

    Following the publication of this article the authors noted that data describing precisely where phosphorylation sites in proteins modulated following JAK1 or JAK3 inhibition in mutant T-ALL samples was not cl...

    S. Degryse, C. E. de Bock, S. Demeyer, I. Govaerts, S. Bornschein, D. Verbeke… in Leukemia (2018)

    Download PDF (173 KB) View Article